

**From the Chief Medical Officer
Prof Sir Michael McBride**



Department of
Health

An Roinn Sláinte

Mánnystrie O Poustie

www.health-ni.gov.uk

HSS(MD) 81/2021 (Addendum)

FOR ACTION

Chief Executives, Public Health Agency/Health and Social
Care Board/HSC Trusts/ NIAS

GP Medical Advisers, Health & Social Care Board

All General Practitioners and GP Locums (for onward
distribution to practice staff)

OOHs Medical Managers (for onward distribution to staff)

PLEASE SEE ATTACHED FULL CIRCULATION LIST

Castle Buildings
Stormont Estate
BELFAST
BT4 3SQ

Tel: 028 9052 0563

Email: Michael.McBride@health-ni.gov.uk

Our Ref: HSS(MD) 81/2021

Date: 24 December 2021

Dear Colleague

**NEUTRALISING MONOCLONAL ANTIBODIES (nMABs) OR ANTIVIRALS FOR
NON-HOSPITALISED PATIENTS WITH COVID-19 – FURTHER ADDENDUM**

This further addendum to HSS(MD) 81/2021 is to advise that the published UK-wide clinical commissioning policy for use of neutralising monoclonal antibodies (nMABs) or antivirals for non-hospitalised patients with COVID-19 has today been updated to remind clinicians that treatments should only be offered where the patient is not already showing signs of clinical improvement and to provide further clarity on haematological disease (appendix 1) and the chemotherapy agents (appendix 2) relevant to determining patient eligibility.

Please refer to the updated version of the policy [here](#).

Yours sincerely

A handwritten signature in black ink, appearing to read 'Michael McBride'.

PROF SIR MICHAEL McBRIDE
Chief Medical Officer

Enclosed: Interim Clinical Commissioning Policy: Neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 (published 24 December 2021)

